Our results demonstrated that CARM1 exerted a significant tumor-promoting role in GC, therefore, we sought to explore the therapeutic effect of targeting CARM1 by utilizing the small molecule compound EZM2302, which is a specific inhibitor of CARM1 and has shown a significant inhibitory effect on multiple myeloma both in vitro and in vivo [21]. Here, CARM1 is linked to AL amyloidosis.